• A
  • A
  • A
日本語 Help
Science and technology information site for articles, patents, researchers information, etc.

Co-authoring Researcher

Co-inventing Researcher

Researcher similar to the Researcher

Article similar to the Researcher

Patent similar to the Researcher

Research Project similar to the Researcher

Article(J-GLOBAL estimation)

Patent(J-GLOBAL estimation)

Rchr
J-GLOBAL ID:202201017745678760   Update date: Feb. 10, 2025

Suzuki Rikio

スズキ リキオ | Suzuki Rikio
Clips
Affiliation and department:
Job title: Associate Professor
Research field  (1): Hematology and oncology
Research theme for competitive and other funds  (2):
  • 2019 - 2022 Development of less invasive treatment for central nervous system invasion of refractory hematologic malignancies.
  • 2018 - 2022 Elucidation and overcoming of drug resistance mechanism mediated by semaphorin 3A signal in multiple myeloma
Papers (43):
  • Tomoyasu Jo, Kyoko Yoshihara, Masaki Ri, Nobuhiro Tsukada, Naoya Mimura, Keiko Fujii, Kentaro Fukushima, Shin-ichiro Fujiwara, Yuji Shimura, Kyoko Haraguchi, et al. Low platelet counts and low CD4/CD8 ratios at apheresis increase the risk of CAR-T cell manufacturing failure in myeloma. Blood Neoplasia. 2024. 100051-100051
  • Toshiro Seki, Rikio Suzuki, Shino Ohshima, Yoshiyuki Manabe, Shion Onoue, Yuki Hoshino, Atsushi Yasuda, Ryoji Ito, Hiroshi Kawada, Hitoshi Ishimoto, et al. Liposome-encapsulated progesterone efficiently suppresses B-lineage cell proliferation. Biochemistry and biophysics reports. 2024. 38. 101710-101710
  • Makoto Onizuka, Eri Kikkawa, Shinichiro Machida, Masako Toyosaki, Rikio Suzuki, Daisuke Ogiya, Yasuyuki Aoyama, Jun Amaki, Kaito Harada, Ryujiro Hara, et al. Association of CDKN2A/2B deletion with relapse after hematopoietic stem cell transplantation for acute lymphoblastic leukemia. Blood cell therapy. 2023. 6. 3. 80-86
  • Daisuke Minakata, Tadao Ishida, Kiyoshi Ando, Rikio Suzuki, Junji Tanaka, Shotaro Hagiwara, Revathi Ananthakrishnan, Shigeki Kuwayama, Mitsufumi Nishio, Yoshinobu Kanda, et al. Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese patients with relapsed and refractory multiple myeloma. International journal of hematology. 2023. 117. 5. 729-737
  • Rikio Suzuki, Daisuke Ogiya, Yoshiaki Ogawa, Hiroshi Kawada, Kiyoshi Ando. Targeting CAM-DR and Mitochondrial Transfer for the Treatment of Multiple Myeloma. Current oncology (Toronto, Ont.). 2022. 29. 11. 8529-8539
more...
Work history (8):
  • 2024/04 - 現在 Tokai University Department of Hematology/Oncology Associate Professor
  • 2019/04 - 2024/03 Tokai University Department of Hematology/Oncology Lecturer
  • 2017/04 - 2019/03 Tokai University Department of Hematology/Oncology Assistant professor
  • 2015/04 - 2017/03 秦野赤十字病院 血液内科
  • 2014/10 - 2015/03 海老名総合病院 血液内科
Show all
Awards (4):
  • 2018 - 日本骨髄腫学会 平成30年度日本骨髄腫学会奨励賞
  • 2017 - 日本血液学会 日本血液学会平成29年度研究助成
  • 2013 - 2013 ASH Abstract Achievement Award
  • 2011 - 先進医薬研究振興財団 平成23年度血液医学分野海外留学助成
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page